Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients

Hematological Oncology

Volumn 31, Issue 4, 2013, Pages 201-205

  Pappa, Ca ^a   Alexandrakis, Mg ^b   Boula, A ^a   Psarakis, Fe ^b   Kolovou, A ^c   Bantouna, V ^b   Stavroulaki, E ^a   Tsirakis, G ^b  

^a Venizelion Hospital of Heraklion   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c General Hospital of Chania   (Greece)

Author keywords

Angiogenesis; Cytokines; Endoglin; Multiple myeloma

Indexed keywords

ANTINEOPLASTIC AGENT; ENDOGLIN; INTERLEUKIN 18; VASCULOTROPIN;

AGED; ARTICLE; BLOOD SAMPLING; BONE MARROW BIOPSY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL INFILTRATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANGIOGENESIS; CYTOKINES; ENDOGLIN; MULTIPLE MYELOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-18; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTORS, CELL SURFACE; RIBONUCLEASE, PANCREATIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84889102929     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2044     Document Type: Article

References (39)

1. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000; 52: 237-268.
2. Kumar S, Witzig TE, Timm M, et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 2004; 85: 800-805.
3. Duff SE, Li C, Garlang JM, et al. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003; 17: 984-992.
4. Burrows FJ, Derbyshire EJ, Tazzari PL, et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995; 12: 1623-1634.
5. Torsney E, Charlton R, Parums D, et al. Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res 2002; 51: 464-470.
6. Perez-Gomez E, Del Castillo G, et al. The role of the TGF-β coreceptor endoglin in cancer. Scientific World Journal 2010; 10: 2367-2384.
7. Levy L, Hill CS. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006; 17: 41-58.
8. Massagué J. TGF beta in cancer. Cell 2008; 134: 215-230.
9. Hawinkels LJ, Kuiper P, Wiercinska E, et al. Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res 2010; 70: 4141-4150.
10. Fonsatti E, Del Vecchio L, Altomonte M, et al. Endoglin: an accessory component of the TGF-beta-binding receptor complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 2001; 188: 1-7.
11. Fonsatti E, Maio M. Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Tranl Med 2004; 2: 18.
12. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642-649.
13. Li C, Guo B, Wilson PB, et al. Plasma levels of soluble CD 105 correlate with metastasis in patients with breast cancer. Int J Cancer 2000; 89: 122-126.
14. Calabrò L, Fonsatti E, Bellomo G, et al. Differential levels of soluble endoglin (CD105) in myeloid malignancies. J Cell Physiol 2003; 194: 171-175.
15. Castonguay R, Werner ED, Matthews RG, et al. Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem 2011; 286: 30034-30046.
16. Kastritis E, Roussou M, Michalis M, et al. On Behalf of the Greek Myeloma Study Group High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients. Br J Haem 2010; 150: 587-591.
17. Dankbar B, Padró T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95: 2630-2636.
18. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol 2003; 73: 213-224.
19. Robertson MJ, Mier JW, Logan T, et al. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res 2006; 12: 4265-4273.
20. Alexandrakis MG, Passam FH, Sfiridaki K, et al. Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival. Leuk Res 2004; 28: 259-266.
21. Amin MA, Rabquer BJ, Mansfield PJ, et al. Interleukin 18 induces angiogenesis in vitro and in vivo via Src and Jnk kinases. Ann Rheum Dis 2010; 69: 2204-2212.
22. Amin MA, Mansfield PJ, Pakozdi A, Campbell PL, Ahmed S, Martinez RJ, et al. Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum 2007; 56: 1787-1797.
23. Folkman J. Angiogenesis and apoptosis. Seminars in Cancer Biology 2003; 13: 159-167.
24. Benelli R, Lorusso G, Albini A, et al. Cytokines and chemokines as regulators of angiogenesis in health and disease. Curr Pharm Des 2006; 12: 3101-3115.
25. Fons P, Herault JP, Delesque N, et al. VEGF-R2 and neuropilin-1 are involved in VEGF-A-induced differentiation of human bone marrow progenitor cells. J Cell Physiol 2004; 200: 351-359.
26. Reyes M, Dudek A, Jahagirdar B, et al. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002; 109: 337-346.
27. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-936.
28. Xia WR, Fu WL, Cai L, et al. Expression, purification and characterization of recombinant human angiogenin in pichia pastoris. Biosci Biotechnol Biochem 2012; 76: 1384-1388.
29. Landt S, Mordelt K, Schwidde I, et al. Prognostic significance of the angiogenic factors angiogenin, endoglin and endostatin in cervical cancer. Anticancer Res 2011; 31: 2651-2655.
30. Rykala J, Przybylowska K, Majsterek I, et al. Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables. Pathol Oncol Res 2011; 17: 809-817.
31. Alexandrakis MG, Passam FH, Sfiridaki A, et al. Elevated serum angiogenin in multiple myeloma. Hematol J 2003; 4: 454-455.
32. Terpos E, Kastritis E, Roussou M, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008; 22: 2247-2256.
33. Alexandrakis MG, Passam FH, Pappa CA, et al. Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes. Leuk Res 2005; 29: 41-46.
34. Musolino C, Alonci A, Bellomo G, et al. Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications. Eur J Haematol 2004; 72: 416-419.
35. Fürstenberger G, von Moos R, Lucas R, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 2006; 94: 524-531.
36. Mysliwiec P, Pawlak K, Kuklinski A, et al. Combined perioperative plasma endoglin and VEGF-A assessment in colorectal cancer patients. Folia Histochem Cytobiol 2008; 46: 487-492.
37. Bellone G, Solerio D, Chiusa L, et al. Transforming growth factor-β binding receptor endoglin (CD105) Expression in esophageal cancer and in adjacent nontumorous esophagus as prognostic predictor of recurrence. Ann Surg Oncol 2007; 143: 3232-3242.
38. Mysliwiec P, Pawlak K, Bandurski R, et al. Soluble angiogenesis markers in gastric tumor patients. Folia Histochem Cytobiol 2009; 47: 81-86.
39. Tsirakis G, Pappa C, Spanoudakis M, et al. Clinical significance of sCD105 in angiogenesis and disease activity in multiple myeloma. Eur J Intern Med 2012; 23: 368-373.